Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I–IIIB breast cancer receiving chemotherapy

Maaike M.G.A. van den Berg, Dieuwertje E. Kok, Liesbeth Posthuma, Lisette Kamps, Celine S. Kelfkens, Nicole Buist, Maud Geenen, Annebeth Haringhuizen, Joan B. Heijns, Rianne H.M.A. van Lieshout, Maartje Los, Dirkje W. Sommeijer, Johanna N.H. Timmer-Bonte, Anja Th C.M. de Kruif, Hanneke W.M. van Laarhoven, Ellen Kampman, Renate M. Winkels

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Purpose: Initial dose of chemotherapy is planned based on body surface area, which does not take body composition into account. We studied the association between fat mass (kg and relative to total body weight) as well as lean mass (kg and relative to total body weight) and toxicity-induced modifications of treatment in breast cancer patients receiving chemotherapy. Methods: In an observational study among 172 breast cancer patients (stage I–IIIB) in the Netherlands, we assessed body composition using dual-energy X-ray scans. Information on toxicity-induced modifications of treatment, defined as dose reductions, cycle delays, regimen switches, or premature termination of chemotherapy, was abstracted from medical records. Adjusted hazard ratios and 95% confidence intervals (95% CI) were calculated to assess associations between body composition and the risk of toxicity-induced modifications of treatment. Results: In total, 95 out of 172 (55%) patients experienced toxicity-induced modifications of treatment. Higher absolute and relative fat mass were associated with higher risk of these modifications (HR 1.14 per 5 kg; 95% CI 1.04–1.25 and HR 1.21 per 5%; 95% CI 1.05–1.38, respectively). A higher relative lean mass was associated with a lower risk of modifications (HR 0.83 per 5%; 95% CI 0.72–0.96). There was no association between absolute lean mass and risk of toxicity-induced modifications of treatment. Conclusions: A higher absolute and a higher relative fat mass was associated with an increased risk of toxicity-induced modifications of treatment. Absolute lean mass was not associated with risk of these treatment modifications, while higher relative lean mass associated with lower risk of modifications. These data suggest that total fat mass importantly determines the risk of toxicities during chemotherapy in breast cancer patients.

Original languageEnglish
Pages (from-to)475-481
Number of pages7
JournalBreast Cancer Research and Treatment
Volume173
Issue number2
Early online date23 Oct 2018
DOIs
Publication statusPublished - 30 Jan 2019

Fingerprint

Body Composition
Breast Neoplasms
Drug Therapy
Fats
Confidence Intervals
Therapeutics
Body Weight
Body Surface Area
Netherlands
Medical Records
Observational Studies
X-Rays

Keywords

  • Body composition
  • Breast cancer
  • Chemotherapy
  • Fat mass
  • Toxicity

Cite this

van den Berg, Maaike M.G.A. ; Kok, Dieuwertje E. ; Posthuma, Liesbeth ; Kamps, Lisette ; Kelfkens, Celine S. ; Buist, Nicole ; Geenen, Maud ; Haringhuizen, Annebeth ; Heijns, Joan B. ; van Lieshout, Rianne H.M.A. ; Los, Maartje ; Sommeijer, Dirkje W. ; Timmer-Bonte, Johanna N.H. ; de Kruif, Anja Th C.M. ; van Laarhoven, Hanneke W.M. ; Kampman, Ellen ; Winkels, Renate M. / Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I–IIIB breast cancer receiving chemotherapy. In: Breast Cancer Research and Treatment. 2019 ; Vol. 173, No. 2. pp. 475-481.
@article{8b98b4f9ed974934ac1393b932f284ec,
title = "Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I–IIIB breast cancer receiving chemotherapy",
abstract = "Purpose: Initial dose of chemotherapy is planned based on body surface area, which does not take body composition into account. We studied the association between fat mass (kg and relative to total body weight) as well as lean mass (kg and relative to total body weight) and toxicity-induced modifications of treatment in breast cancer patients receiving chemotherapy. Methods: In an observational study among 172 breast cancer patients (stage I–IIIB) in the Netherlands, we assessed body composition using dual-energy X-ray scans. Information on toxicity-induced modifications of treatment, defined as dose reductions, cycle delays, regimen switches, or premature termination of chemotherapy, was abstracted from medical records. Adjusted hazard ratios and 95{\%} confidence intervals (95{\%} CI) were calculated to assess associations between body composition and the risk of toxicity-induced modifications of treatment. Results: In total, 95 out of 172 (55{\%}) patients experienced toxicity-induced modifications of treatment. Higher absolute and relative fat mass were associated with higher risk of these modifications (HR 1.14 per 5 kg; 95{\%} CI 1.04–1.25 and HR 1.21 per 5{\%}; 95{\%} CI 1.05–1.38, respectively). A higher relative lean mass was associated with a lower risk of modifications (HR 0.83 per 5{\%}; 95{\%} CI 0.72–0.96). There was no association between absolute lean mass and risk of toxicity-induced modifications of treatment. Conclusions: A higher absolute and a higher relative fat mass was associated with an increased risk of toxicity-induced modifications of treatment. Absolute lean mass was not associated with risk of these treatment modifications, while higher relative lean mass associated with lower risk of modifications. These data suggest that total fat mass importantly determines the risk of toxicities during chemotherapy in breast cancer patients.",
keywords = "Body composition, Breast cancer, Chemotherapy, Fat mass, Toxicity",
author = "{van den Berg}, {Maaike M.G.A.} and Kok, {Dieuwertje E.} and Liesbeth Posthuma and Lisette Kamps and Kelfkens, {Celine S.} and Nicole Buist and Maud Geenen and Annebeth Haringhuizen and Heijns, {Joan B.} and {van Lieshout}, {Rianne H.M.A.} and Maartje Los and Sommeijer, {Dirkje W.} and Timmer-Bonte, {Johanna N.H.} and {de Kruif}, {Anja Th C.M.} and {van Laarhoven}, {Hanneke W.M.} and Ellen Kampman and Winkels, {Renate M.}",
year = "2019",
month = "1",
day = "30",
doi = "10.1007/s10549-018-5014-5",
language = "English",
volume = "173",
pages = "475--481",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

van den Berg, MMGA, Kok, DE, Posthuma, L, Kamps, L, Kelfkens, CS, Buist, N, Geenen, M, Haringhuizen, A, Heijns, JB, van Lieshout, RHMA, Los, M, Sommeijer, DW, Timmer-Bonte, JNH, de Kruif, ATCM, van Laarhoven, HWM, Kampman, E & Winkels, RM 2019, 'Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I–IIIB breast cancer receiving chemotherapy' Breast Cancer Research and Treatment, vol. 173, no. 2, pp. 475-481. https://doi.org/10.1007/s10549-018-5014-5

Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I–IIIB breast cancer receiving chemotherapy. / van den Berg, Maaike M.G.A.; Kok, Dieuwertje E.; Posthuma, Liesbeth; Kamps, Lisette; Kelfkens, Celine S.; Buist, Nicole; Geenen, Maud; Haringhuizen, Annebeth; Heijns, Joan B.; van Lieshout, Rianne H.M.A.; Los, Maartje; Sommeijer, Dirkje W.; Timmer-Bonte, Johanna N.H.; de Kruif, Anja Th C.M.; van Laarhoven, Hanneke W.M.; Kampman, Ellen; Winkels, Renate M.

In: Breast Cancer Research and Treatment, Vol. 173, No. 2, 30.01.2019, p. 475-481.

Research output: Contribution to JournalArticleAcademicpeer-review

TY - JOUR

T1 - Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I–IIIB breast cancer receiving chemotherapy

AU - van den Berg, Maaike M.G.A.

AU - Kok, Dieuwertje E.

AU - Posthuma, Liesbeth

AU - Kamps, Lisette

AU - Kelfkens, Celine S.

AU - Buist, Nicole

AU - Geenen, Maud

AU - Haringhuizen, Annebeth

AU - Heijns, Joan B.

AU - van Lieshout, Rianne H.M.A.

AU - Los, Maartje

AU - Sommeijer, Dirkje W.

AU - Timmer-Bonte, Johanna N.H.

AU - de Kruif, Anja Th C.M.

AU - van Laarhoven, Hanneke W.M.

AU - Kampman, Ellen

AU - Winkels, Renate M.

PY - 2019/1/30

Y1 - 2019/1/30

N2 - Purpose: Initial dose of chemotherapy is planned based on body surface area, which does not take body composition into account. We studied the association between fat mass (kg and relative to total body weight) as well as lean mass (kg and relative to total body weight) and toxicity-induced modifications of treatment in breast cancer patients receiving chemotherapy. Methods: In an observational study among 172 breast cancer patients (stage I–IIIB) in the Netherlands, we assessed body composition using dual-energy X-ray scans. Information on toxicity-induced modifications of treatment, defined as dose reductions, cycle delays, regimen switches, or premature termination of chemotherapy, was abstracted from medical records. Adjusted hazard ratios and 95% confidence intervals (95% CI) were calculated to assess associations between body composition and the risk of toxicity-induced modifications of treatment. Results: In total, 95 out of 172 (55%) patients experienced toxicity-induced modifications of treatment. Higher absolute and relative fat mass were associated with higher risk of these modifications (HR 1.14 per 5 kg; 95% CI 1.04–1.25 and HR 1.21 per 5%; 95% CI 1.05–1.38, respectively). A higher relative lean mass was associated with a lower risk of modifications (HR 0.83 per 5%; 95% CI 0.72–0.96). There was no association between absolute lean mass and risk of toxicity-induced modifications of treatment. Conclusions: A higher absolute and a higher relative fat mass was associated with an increased risk of toxicity-induced modifications of treatment. Absolute lean mass was not associated with risk of these treatment modifications, while higher relative lean mass associated with lower risk of modifications. These data suggest that total fat mass importantly determines the risk of toxicities during chemotherapy in breast cancer patients.

AB - Purpose: Initial dose of chemotherapy is planned based on body surface area, which does not take body composition into account. We studied the association between fat mass (kg and relative to total body weight) as well as lean mass (kg and relative to total body weight) and toxicity-induced modifications of treatment in breast cancer patients receiving chemotherapy. Methods: In an observational study among 172 breast cancer patients (stage I–IIIB) in the Netherlands, we assessed body composition using dual-energy X-ray scans. Information on toxicity-induced modifications of treatment, defined as dose reductions, cycle delays, regimen switches, or premature termination of chemotherapy, was abstracted from medical records. Adjusted hazard ratios and 95% confidence intervals (95% CI) were calculated to assess associations between body composition and the risk of toxicity-induced modifications of treatment. Results: In total, 95 out of 172 (55%) patients experienced toxicity-induced modifications of treatment. Higher absolute and relative fat mass were associated with higher risk of these modifications (HR 1.14 per 5 kg; 95% CI 1.04–1.25 and HR 1.21 per 5%; 95% CI 1.05–1.38, respectively). A higher relative lean mass was associated with a lower risk of modifications (HR 0.83 per 5%; 95% CI 0.72–0.96). There was no association between absolute lean mass and risk of toxicity-induced modifications of treatment. Conclusions: A higher absolute and a higher relative fat mass was associated with an increased risk of toxicity-induced modifications of treatment. Absolute lean mass was not associated with risk of these treatment modifications, while higher relative lean mass associated with lower risk of modifications. These data suggest that total fat mass importantly determines the risk of toxicities during chemotherapy in breast cancer patients.

KW - Body composition

KW - Breast cancer

KW - Chemotherapy

KW - Fat mass

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85055738655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055738655&partnerID=8YFLogxK

U2 - 10.1007/s10549-018-5014-5

DO - 10.1007/s10549-018-5014-5

M3 - Article

VL - 173

SP - 475

EP - 481

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -